Edition:
India

Chugai Pharmaceutical Co Ltd (4519.T)

4519.T on Tokyo Stock Exchange

5,870JPY
18 May 2018
Change (% chg)

¥-10 (-0.17%)
Prev Close
¥5,880
Open
¥5,850
Day's High
¥5,900
Day's Low
¥5,830
Volume
965,500
Avg. Vol
881,229
52-wk High
¥6,080
52-wk Low
¥4,065

Latest Key Developments (Source: Significant Developments)

Pharma Mar Says Chugai Terminates Licensing Agreement For Zepsyre In Japan
Friday, 27 Apr 2018 

April 27 (Reuters) - Pharma Mar SA ::SAYS SUBMITS INFORMATION REGARDING THE TERMINATION OF THE LICENSING AGREEMENT FOR JAPAN ENTERED INTO WITH CHUGAI IN RELATION TO ZEPSYRE.EFFECTIVE DATE OF TERMINATION IS IN APRIL 2019.TERMINATION DOES NOT AFFECT ANY PAYMENTS RECEIVED BY PHARMAMAR.TO INITIATE NEGOTIATIONS IN THE SHORT TERM WITH OTHER POTENTIAL LICENSEES FOR ZEPSYRE IN JAPAN.TO CONTINUE WITH PHASE I CLINICAL TRIALS INITIATED IN JAPAN IN 2017 FOR JAPANESE PATIENTS.  Full Article

CHUGAI PHARMACEUTICAL says filing of patent infringement lawsuit and petition for provisional disposition order
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - CHUGAI PHARMACEUTICAL Co Ltd <4519.T> ::Says it filed an application for assisting intervention with Zenyaku Kogyo Co Ltd in a lawsuit that Genentech Inc filed, wherein the plaintiff demands prohibition of sales etc. of Rituxan® Injection, against Sandoz K.K and Kyowa Hakko Kirin Co Ltd.Says the company has also filed an application for assisting intervention in a petition for provisional disposition order that has been filed with the lawsuit.  Full Article

Chiome Bioscience says termination of joint research contract
Monday, 18 Dec 2017 

Dec 18 (Reuters) - Chiome Bioscience Inc <4583.T>:Says it announces termination of candidate antibody related joint research contract, which was signed between the co and CHUGAI PHARMACEUTICAL CO LTD <<<4519.T>>>, as the contract has expired on Dec. 31 .  Full Article

Chugai Pharmaceutical says change of chief executive officer
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>:Says it names current president and chief operating officer Tatsuro Kosaka as chief executive officer and president, effective late March 2018.  Full Article

R&I affirms Chugai Pharmaceutical's rating at "AA-" and says stable outlook -R&I
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>:Says Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "AA-" -R&I.Says rating outlook stable -R&I.  Full Article

Marketing and manufacturing right transfer of 13 long-term listed products from Chugai Pharmaceutical to Taiyo Pharma
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>:Says it and TAIYO HOLDINGS CO LTD <<<4626.T>>> announced today that they have entered into an agreement, under which the co and F. Hoffmann-La Roche, Ltd. will transfer the marketing authorizations, including marketing and manufacturing rights, of 13 long-term listed products manufactured and marketed in Japan by Chugai to TAIYO Pharma Co., Ltd., a wholly owned subsidiary of Taiyo Holdings.  Full Article

Chugai Pharmaceutical to retire treasury shares
Tuesday, 25 Apr 2017 

April 25(Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>:Says it will retire 123,000 shares (0.02 percent of outstanding) of its common stock on April 28.  Full Article

Chugai and Galderma announce global license agreement for Nemolizumab
Thursday, 21 Jul 2016 

Chugai Pharmaceutical Co Ltd <4519.T>: Chugai will continue to be responsible for product manufacturing and supply of Nemolizumab. . Under terms of agreement, Chugai will receive an upfront, milestone and royalty payments from Galderma. . Chugai and Galderma announce global license agreement for Nemolizumab (cim331), novel biologic for skin diseases . Chugai and Galderma announce global license agreement for Nemolizumab (cim331), novel biologic for skin diseases .Chugai will grant Galderma license for development and marketing of nemolizumab worldwide, exception of Japan and Taiwan.  Full Article

Chugai Pharmaceutical says concluded a license agreement with Roche
Wednesday, 1 Jun 2016 

Chugai Pharmaceutical Co Ltd: Announced that it concluded a license agreement with roche for "sa237" .Per the terms of the agreement, chugai will receive an upfront fee, milestone and royalty payments from roche..  Full Article

BRIEF-Chugai Pharmaceutical To Invest 25 Bln Yen Into A Singapore Research Center By 2021-Nikkei‍​

* CHUGAI PHARMACEUTICAL LOOKS TO INVEST SOME 25 BILLION YEN INTO A SINGAPORE RESEARCH CENTER FOR BIOPHARMACEUTICALS BY 2021 - NIKKEI‍​ Source text :(s.nikkei.com/2CitZyn) Further company coverage: (bangalore.newsroom@thomsonreuters.com)